OPKO Health sells NGENLA growth hormone treatment, Rayaldee kidney disease treatment and specialty lab tests for doctors and patients. OPK reports earnings on Wed, Nov 4, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 16 | Piper Sandler | Reiterated | Buy |
Whale Options Flow
90DNo whale options trades in OPK in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OPK is in one of them and how their past OPK trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered OPK in an article yet. Here's the latest on the wider market.
About Opko Health
OPKO Health is a healthcare company based in Miami, Florida. It sells NGENLA, a weekly growth hormone treatment for children, and Rayaldee, a treatment for secondary hyperparathyroidism in adults with chronic kidney disease. Its laboratory business provides clinical and women's health testing in New York and New Jersey, along with the 4Kscore prostate cancer test, which is offered across the United States. The company is also developing therapies for cancer and infectious disease.
- Headquarters
- Miami, FL